Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
[HTML][HTML] PI3K/AKT/mTOR-targeted therapy for breast cancer
K Zhu, Y Wu, P He, Y Fan, X Zhong, H Zheng, T Luo - Cells, 2022 - mdpi.com
Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
Proteogenomics connects somatic mutations to signalling in breast cancer
Somatic mutations have been extensively characterized in breast cancer, but the effects of
these genetic alterations on the proteomic landscape remain poorly understood. Here we …
these genetic alterations on the proteomic landscape remain poorly understood. Here we …
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Background AKT, also known as protein kinase B, is a key element of the PI3K/AKT
signaling pathway. Moreover, AKT regulates the hallmarks of cancer, eg tumor growth …
signaling pathway. Moreover, AKT regulates the hallmarks of cancer, eg tumor growth …
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR …
Background Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the
tumor, which in most cases results from its dependence on an oncogene and/or loss of a …
tumor, which in most cases results from its dependence on an oncogene and/or loss of a …
The PI3K/AKT pathway as a target for cancer treatment
IA Mayer, CL Arteaga - Annual review of medicine, 2016 - annualreviews.org
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor,
which in most cases results from its dependence on an oncogene and/or loss of a tumor …
which in most cases results from its dependence on an oncogene and/or loss of a tumor …
[HTML][HTML] The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cancer stem cells (CSCs) are proposed to drive tumor initiation and progression. Yet, our
understanding of the cellular and molecular mechanisms that underlie CSC properties is …
understanding of the cellular and molecular mechanisms that underlie CSC properties is …
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives
Gene expression profiling has reshaped our understanding of breast cancer by defining and
characterizing four main intrinsic molecular subtypes: human epidermal growth factor …
characterizing four main intrinsic molecular subtypes: human epidermal growth factor …
Endocrine resistance in breast cancer–an overview and update
Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α;
ERα) represent the single largest molecular subtype of breast cancer. More women …
ERα) represent the single largest molecular subtype of breast cancer. More women …